NCT01136395 - Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

June 18, 2019

Study Completion Date

June 18, 2019

Conditions

Kidney TransplantationRituximab (RTx)Living DonorsImmunologyVirus

Interventions

DRUG

Rituximab

375mg/m2 4 weeks before ABOi LD transplantation

PROCEDURE

living donor transplantation

living donor transplantation (ABO compatible) to be compared with deceased donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK/JC), respectively

PROCEDURE

deceased donor transplantation

deceased donor transplantation (ABO compatible) to be compared with living donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK virus (BKV), JC virus (JCV)), respectively

Trial Locations (1)

D-35392

Department of Internal Medicine, University of Giessen, Giessen